A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC). This is an ASCO Meeting Abstract ...
The NFκB pathway as a key mediator of the glioblastoma mesenchymal subtype in glioblastoma stem cells and human tumors. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This ...